Top

Published in:

01-09-2012 | Translational Research and Biomarkers

Reduced Expression of PER3 Is Associated with Incidence and Development of Colon Cancer

Authors: Xiaoliang Wang, PhD, Dongwang Yan, PhD, Mujian Teng, PhD, Junwei Fan, PhD, Chongzhi Zhou, PhD, Dawei Li, PhD, Guoqiang Qiu, MD, Xing Sun, PhD, Tao Li, PhD, Tonghai Xing, PhD, Huamei Tang, MD, Xiao Peng, MD, Zhihai Peng, MD, PhD, FACS

Published in: Annals of Surgical Oncology | Issue 9/2012

Abstract

Background

Period 3 (PER3), a circadian regulation protein, influences cell cycle, growth, and differentiation. The aim of the present study was to determine whether PER3 expression is associated with colon cancer incidence and progression.

Methods

PER3 expression was analyzed in the normal and cancerous tissues from patients with colon cancer by establishing a long serial analysis of gene expression (SAGE) database as well as by real-time PCR and immunohistochemistry.

Results

As compared with normal tissue, a 2.8-fold decrease in PER3 mRNA levels in colon cancerous tissue was observed. Real-time PCR analysis revealed that PER3 mRNA levels in tumor tissues were lower than in normal tissues (P < 0.001) in both patients with colon tumor and those with rectal tumor. In addition, PER3 expression was related to multiple clinicopathologic factors, including tumor location, differentiation, and stage. Furthermore, the incidence of death was higher in subjects with PER3-negative tumors (P = 0.025); the estimated overall survival time was 71.5 ± 2.2 months and 58.6 ± 5.0 months in subjects with PER3-positive and PER3-negative tumors, respectively (P = 0.020).

Conclusions

PER3 may play a role in colon cancer progression.

Nelson RS, Thorson AG. Colorectal cancer screening. Curr Oncol Rep. 2009;11:482–9.PubMedCrossRef

Labianca R, Beretta GD, Kildani B, et al. Colon cancer. Crit Rev Oncol Hematol. 2010;74:106–33.PubMedCrossRef

Li M, Gu J. Changing patterns of colorectal cancer in China over a period of 20 years. World J Gastroenterol. 2005;11:4685–8.PubMed

Fan J, Peng Z, Zhou C, et al. Gene-expression profiling in Chinese patients with colon cancer by coupling experimental and bioinformatic genomewide gene-expression analyses: identification and validation of IFITM3 as a biomarker of early colon carcinogenesis. Cancer. 2008;113:266–75.PubMedCrossRef

Eriguchi M, Levi F, Hisa T, Yanagie H, Nonaka Y, Takeda Y. Chronotherapy for cancer. Biomed Pharmacother. 2003;57:92 s–5 s.PubMedCrossRef

Archer SN, Robilliard DL, Skene DJ, et al. A length polymorphism in the circadian clock gene Per3 is linked to delayed sleep phase syndrome and extreme diurnal preference. Sleep. 2003;26:413–5.PubMed

Ebisawa T, Uchiyama M, Kajimura N, et al. Association of structural polymorphisms in the human period3 gene with delayed sleep phase syndrome. EMBO Rep. 2001;2:342–6.PubMedCrossRef

Johansson C, Willeit M, Smedh C, et al. Circadian clock–related polymorphisms in seasonal affective disorder and their relevance to diurnal preference. Neuropsychopharmacology. 2003;28:734–9.PubMedCrossRef

Chen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ, Chang JG. Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis. 2005;26:1241–6.PubMedCrossRef

10.

Zhu Y, Brown HN, Zhang Y, Stevens RG, Zheng T. Period3 structural variation: a circadian biomarker associated with breast cancer in young women. Cancer Epidemiol Biomarkers Prev. 2005;14:268–70.PubMed

11.

Lin YM, Chang JH, Yeh KT, et al. Disturbance of circadian gene expression in hepatocellular carcinoma. Mol Carcinog. 2008;47:925–33.PubMedCrossRef

12.

Tokunaga H, Takebayashi Y, Utsunomiya H, et al. Clinicopathological significance of circadian rhythm–related gene expression levels in patients with epithelial ovarian cancer. Acta Obstet Gynecol Scand. 2008;87:1060–70.PubMedCrossRef

13.

Zhu Y, Stevens RG, Hoffman AE, et al. Testing the circadian gene hypothesis in prostate cancer: a population-based case-control study. Cancer Res. 2009;69:9315–22.PubMedCrossRef

14.

Fu L, Lee CC. The circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer. 2003;3:350–61.PubMedCrossRef

15.

Yang MY, Chang JG, Lin PM, et al. Down-regulation of circadian clock genes in chronic myeloid leukemia: alternative methylation pattern of hPER3. Cancer Sci. 2006;97:1298–307.PubMedCrossRef

16.

Engstrom PF, Benson AB 3rd, Chen YJ, et al. Colon cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2005;3:468–91.PubMed

17.

Li D, Yan D, Tang H, et al. IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis. Ann Surg Oncol. 2009;16:3499–506.PubMedCrossRef

18.

Reppert SM, Weaver DR. Coordination of circadian timing in mammals. Nature. 2002;418:935–41.PubMedCrossRef

19.

Barnes JW, Tischkau SA, Barnes JA, et al. Requirement of mammalian Timeless for circadian rhythmicity. Science. 2003;302:439–42.PubMedCrossRef

20.

Garceau NY, Liu Y, Loros JJ, Dunlap JC. Alternative initiation of translation and time-specific phosphorylation yield multiple forms of the essential clock protein frequency. Cell. 1997;89:469–76.PubMedCrossRef

21.

Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, Okamura H. Control mechanism of the circadian clock for timing of cell division in vivo. Science. 2003;302:255–9.PubMedCrossRef

22.

Sahar S, Sassone-Corsi P. Metabolism and cancer: the circadian clock connection. Nat Rev Cancer. 2009;9:886–96.PubMedCrossRef

23.

Shih HC, Choo KB, Chang TJ, et al. Disturbance of circadian gene expression in endometrial cancer: detection by real-time quantitative RT-PCR. Oncol Rep. 2005;14:1533–8.PubMed

24.

Im JS, Jung BH, Kim SE, Lee KH, Lee JK. Per3, a circadian gene, is required for Chk2 activation in human cells. FEBS Lett. 2010;584:4731–4.PubMedCrossRef

25.

Keith LG, Oleszczuk JJ, Laguens M. Circadian rhythm chaos: a new breast cancer marker. Int J Fertil Womens Med. 2001;46:238–47.PubMed

Title: Reduced Expression of PER3 Is Associated with Incidence and Development of Colon Cancer
Authors: Xiaoliang Wang, PhD
Dongwang Yan, PhD
Mujian Teng, PhD
Junwei Fan, PhD
Chongzhi Zhou, PhD
Dawei Li, PhD
Guoqiang Qiu, MD
Xing Sun, PhD
Tao Li, PhD
Tonghai Xing, PhD
Huamei Tang, MD
Xiao Peng, MD
Zhihai Peng, MD, PhD, FACS
Publication date: 01-09-2012
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 9/2012
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-012-2279-5

ACC 2024 Congress

Springer Medicine

Reduced Expression of PER3 Is Associated with Incidence and Development of Colon Cancer

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2012

The Role of Gender in Primary Hyperparathyroidism: Same Disease, Different Presentation

Outcome of Pure Mucinous Breast Carcinoma Compared to Infiltrating Ductal Carcinoma: A Population-based Study from China

Use of Magnetic Resonance Imaging in Detection of Breast Cancer Recurrence: A Systematic Review

Combined Hepatocellular Carcinoma and Cholangiocarcinoma: Clinical Features, Treatment Modalities, and Prognosis

Coexpression of Stemness Factors Oct4 and Nanog Predict Liver Resection

MicroRNA-10b is a Prognostic Indicator in Colorectal Cancer and Confers Resistance to the Chemotherapeutic Agent 5-Fluorouracil in Colorectal Cancer Cells